Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-28
2007-08-28
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253010, C544S121000, C544S231000
Reexamination Certificate
active
11135272
ABSTRACT:
Triazaspiro[5.5]undecane derivatives of the formula (I), quaternary ammonium salts thereof, N-oxides thereof, non-toxic salts thereof, or pharmaceutical compositions comprising them, as active ingredients (wherein R1is formula (II) or formula (III); R2is alkyl or alkynyl etc.; R3, R4is H, (substituted) alkyl etc., or R3and R4together to form formula (IV); R5is H or alkyl).Therefore the compounds of the formula (I) regulate the effect of chemokine/chemokine receptor, they are used for prevention and treatment of various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis or rheumatoid arthritis etc.
REFERENCES:
patent: 6288083 (2001-09-01), Luly et al.
patent: 6288084 (2001-09-01), Luly et al.
patent: 2004/0097511 (2004-05-01), Habashita et al.
patent: 2004/0106619 (2004-06-01), Mitsuya et al.
patent: 1 236 726 (2002-09-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 98/25605 (1998-06-01), None
patent: WO 98/31364 (1998-07-01), None
patent: WO 00/14086 (2000-03-01), None
patent: WO 01/40227 (2001-06-01), None
patent: WO 02/074769 (2002-09-01), None
Maeda et al, “Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Antagonistic Effects on CCR5” Journal of Biological Chemistry, vol. 276(37), pp. 35194-35200 (2001).
Cascieri and Springer, “The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention” Current Opinion in Chemical Biology, vol. 4(4), pp. 420-427 (2000).
Horuk and Ng, “Chemokine Receptor Antagonists” Medicinal Research Reviews, vol. 20(2), pp. 155-168 (2000).
Kenji Maeda et al., Novel low molecular weight spirodiketopiperazine derivatives potentially inhibit R5 HIV-1 infection through their antagonistic effects on CCR5, The Journal of Biological Chemistry, 2001, vol. 276, No. 37, pp. 35194 to 35200.
Habashita Hiromu
Hamano Shin-ichi
Shibayama Shiro
Takaoka Yoshikazu
Ono Pharmaceutical Co. Ltd.
Tucker Zachary C
LandOfFree
Triazaspiro[5.5]undecane derivative and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazaspiro[5.5]undecane derivative and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazaspiro[5.5]undecane derivative and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882198